Siponimod for multiple sclerosis
- 11 June 2020
- journal article
- research article
- Published by Wiley in Emergencias
- Vol. 2020 (6)
- https://doi.org/10.1002/14651858.cd013647
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:Keywords
This publication has 33 references indexed in Scilit:
- Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced NeurodegenerationFrontiers in Immunology, 2020
- Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosisJournal of Neuroinflammation, 2016
- Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisEmergencias, 2013
- Immunohistochemical detection of sphingosine‐1‐phosphate receptor 1 and 5 in human multiple sclerosis lesionsNeuropathology and Applied Neurobiology, 2013
- The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rateBritish Journal of Pharmacology, 2012
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemBritish Journal of Pharmacology, 2009
- Grading quality of evidence and strength of recommendationsBMJ, 2004
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986